Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Inclusion Criteria:

1. Age 18-65, any gender;
2. Patients with lymphoma/multiple myeloma requiring autologous hematopoietic stem cell transplantation;
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 before transplantation;
4. Basic normal function of heart, lungs, liver, and kidneys (no severe heart disease, no severe lung disease; transaminases ≤ 3× upper limit of normal, blood bilirubin ≤ 2.0 mg/dl; blood creatinine ≤ 2× upper limit of normal);
5. Pre-transplant blood counts meet the following criteria: ANC (Absolute Neutrophil Count) ≥ 1.5×10\^9/L, HGB (Hemoglobin) ≥ 90g/L, PLT (Platelets) ≥ 100×10\^9/L;
6. No other severe diseases that conflict with this protocol;
7. Expected survival of ≥ 3 months and willingness to follow-up;
8. Voluntary participation in this clinical trial and signing of informed consent;
9. The investigator believes that the subject will benefit from participation.

Exclusion Criteria:

1. Patients with splenomegaly;
2. Individuals who have previously undergone allogeneic or autologous hematopoietic stem cell transplantation;
3. HIV antibody-positive, HbsAg-positive, or HCV antibody-positive;
4. Impaired liver or kidney function (transaminases \>3× ULN or blood bilirubin \>2.0 mg/dl; blood creatinine \>2× ULN);
5. Decompensated heart failure, dilated cardiomyopathy, coronary artery disease with ST-segment depression on electrocardiogram, or myocardial infarction within the last Six months;
6. Clinical symptoms of cognitive impairment or severe mental illness;
7. Allergic reactions to polyethylene glycol recombinant human granulocyte colony-stimulating factor injection or recombinant human granulocyte colony-stimulating factor injection;
8. Pregnant or breastfeeding women;
9. Investigators believe participation in this clinical trial is unsuitable.